A Phase Ib Exploratory Trial of SP 333 in Patients with Ulcerative Colitis

Trial Profile

A Phase Ib Exploratory Trial of SP 333 in Patients with Ulcerative Colitis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Dolcanatide (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Synergy Pharmaceuticals Inc
  • Most Recent Events

    • 25 Feb 2016 Planned number of patients changed from 24 to 28, as reported by Synergy Pharmaceuticals media release.
    • 11 Jan 2016 According to a Synergy Pharmaceuticals media release, the company announced positive data from this trial (n=28) for the treatment of mild-to-moderate ulcerative colitis.
    • 11 May 2015 Recruitment is continuing, according to a Synergy Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top